EGFR and non-small cell lung carcinoma: Although in a different patient population, with EGFR-mutated NSCLC, preliminary data suggest savolitinib in combination with osimertinib, a third-generation EGFR tyrosine kinase inhibitor, is well tolerated in Japanese patients (27).